Following the characterization of MIA mice, the study assessed the therapeutic potential of MT-II on these autism-like features
Eli Lilly paid up to $1.925 billion for Versanis Bio in 2023 to acquire bimagrumab, an antibody targeting activin type II receptors
Withdrawal risk is a medical issue that warrants a conversation with a healthcare provider, not something to manage alone based on a medication side effect
Reading is reported in EU/mg of peptide on the Certificate of Analysis at cell-culture-reference acceptance limits, which supports use of Tesamorelin in pituitary somatotroph cell models, GHRH receptor binding assays, and other workflows where LPS-driven confounding signals would otherwise compromise the readout
Breast cancer was diagnosed in 1.65% of women who had received a GLP-1 prescription compared with 2.6% of women who had not
Dose adjustment, slower titration, management of confounding factors, and psychological support often resolve anxiety while maintaining the metabolic benefits of treatment